Kevin J. Fitzgerald
Kevin J. Fitzgerald publishes mostly in Molecular Biology, Organic Chemistry and Cancer Research, on topics such as RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques and Monoclonal and Polyclonal Antibodies Research.
- World rank
- #76,470 of 7,710,434 ranked researchers
- Rank in United States
- #29,510 of 1,627,098
- Works
- 157
- Citations
- 23k
- Citations per work
- 144.7
What does Kevin J. Fitzgerald research?
Kevin J. Fitzgerald's work is mostly in Biochemistry, Genetics and Molecular Biology (42%), Medicine (8%), Chemistry (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Life Sciences7246.1%
- Everything else6239.6%
- Health Sciences138.1%
- Medicine138.1%
- Physical Sciences106.2%
- Chemistry106.2%
- 1Molecular Biology37% of their works
- 2Organic Chemistry6% of their works
- 3Cancer Research5% of their works
- 4Immunology5% of their works
- 5Radiology, Nuclear Medicine and Imaging4% of their works
- 6Cardiology and Cardiovascular Medicine4% of their works
Research topics
- RNA Interference and Gene Delivery
- Advanced biosensing and bioanalysis techniques
- Monoclonal and Polyclonal Antibodies Research
- MicroRNA in disease regulation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Synthesis and Characterization of Heterocyclic Compounds
- Genetics, Aging, and Longevity in Model Organisms
- RNA modifications and cancer
Which keywords describe Kevin J. Fitzgerald's research?
The keywords of their largest research topics: RNA Interference, siRNA Delivery, DNA nanotechnology, Self-Assembly, Fc Receptors, Therapeutic Antibodies, Gene Expression and MicroRNA.
- m6A-seq
- Oxidative Stress
- Triazines
- Synthesis
- MicroRNA
- Therapeutic Antibodies
- Self-Assembly
- siRNA Delivery
- RNA Interference
- DNA nanotechnology
- Fc Receptors
- Gene Expression
- Cardiac Amyloidosis
- Transthyretin
- Aging
- RNA methylation
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 16 words, with their numbers
- RNA Interference381 topic
- siRNA Delivery381 topic
- DNA nanotechnology241 topic
- Self-Assembly241 topic
- Fc Receptors181 topic
- Therapeutic Antibodies181 topic
- Gene Expression131 topic
- MicroRNA131 topic
- Cardiac Amyloidosis81 topic
- Synthesis81 topic
- Transthyretin81 topic
- Triazines81 topic
- Aging71 topic
- Oxidative Stress71 topic
- RNA methylation71 topic
- m6A-seq71 topic
Where does Kevin J. Fitzgerald work?
Kevin J. Fitzgerald's main affiliation in the publication record is Alnylam Pharmaceuticals (United States), United States.
How many publications and citations does Kevin J. Fitzgerald have?
OpenAlex counts 157 works and 22,725 citations for Kevin J. Fitzgerald, an h-index of 55, ranking #76,470 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Kevin J. Fitzgerald. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.